Alumis Halts Undisclosed Drug Program, Tepezza Rivalry Ends Alumis Inc. stopped its undisclosed drug program. This program targeted Thyroid Eye Disease (TED). It was a planned Tepezza competitor. Phase 3 development will not proceed. Alumis Inc. has ceased development of its undisclosed drug program, a potential rival to Amgen's Tepezza for Thyroid Eye Disease (TED). The company will not advance to Phase 3 trials, effectively ending its pursuit in this indication. This decision follows an internal assessment of the program's prospects, though specific metrics or endpoints triggering the halt were not disclosed. The drug was in late-stage preclinical or early clinical development. This halt signifies a voluntary withdrawal by Alumis, pre-empting any formal regulatory action from agencies like the FDA or EMA. Such decisions often occur after Phase 2 data review or strategic portfolio re-evaluation. Alumis will likely inform relevant regulatory bodies of the program's discontinuation. No EMA actions for this specific drug were found in BrunoSan's database, as it did not reach advanced regulatory stages. The cessation removes a significant potential competitor from the lucrative TED market. This strengthens Amgen's Tepezza (teprotumumab-trbw) position, which currently dominates the space. Horizon Therapeutics (now Amgen) acquired Tepezza. Other potential competitors include Viridian Therapeutics' VRDN-001. Alumis will now explore strategic alternatives for its pipeline.